What Omics Bank does

Omics Bank is a New York-headquartered, private healthcare data infrastructure company that provides AI-ready multi-omic and clinical datasets sourced primarily from Asia and the Middle East. Its core product is a unified data platform comprising seven interconnected offerings: OMOP CDM-structured longitudinal EHRs enriched with clinical outcomes, digitized pathology slides and reports, genomics (FASTQ/VCF/BAM), transcriptomics, proteomics, annotated radiology imaging (DICOM/PNG/JPEG), and BioBank biospecimens (tissue, blood, plasma) with metadata. The platform targets populations that represent less than 2% of global genome-wide association studies, addressing a structural underrepresentation gap in pharma research and AI training data.

Underlying the platform is a proprietary technology stack: Agentic AI and LLMs for EHR extraction (claiming 100% accuracy), OMOP Common Data Model standardization, and patent-pending anonymization and de-identification software. Data is normalized against ICD-10, HL7, SNOMED, and FHIR standards and backed by HIPAA, GDPR, and ISO 27001 certifications, with a digital audit trail for consent. The platform currently reaches 187 million patient lives across 35+ countries via the BC Platforms partnership, including 12 million patients from India and 500,000 from the UAE, drawn from 90+ hospitals.

Omics Bank operates an enterprise data-licensing model targeting four primary segments: pharmaceutical/life sciences companies (drug discovery), clinical research organizations (clinical development), clinical trial sponsors (patient recruitment), and healthcare AI companies (model training data). Revenue is generated through data access and licensing fees, with a consultative 'Book a Call' / 'Request Sample Data' sales motion. Distribution is supplemented by channel partnerships with BC Platforms (reselling), Owkin (AI drug discovery co-marketing), and 4baseCare (genomics), and the company cites ~50% cost advantage versus US/EU public data and a 90% reduction in clinical trial recruitment time as key economic value drivers.

Name

Omics Bank

Legal name

Omics Bank

Website

https://omicsbank.com

Company type

Private

Operating status

Operating

Short description

Omics Bank provides AI-ready multi-omic and clinical datasets from Asia and the Middle East to pharmaceutical companies, CROs, and healthcare AI firms for drug discovery, precision medicine, and clinical trials.

Ownership category

akta.pro rank

Product category

Healthcare Data Infrastructure

NAICS

Medical and Diagnostic Laboratories (6215), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (51821)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), De-identification, Tokenization & Privacy-Preserving Data Platforms (HLACAIAK)

Keywords

• Multi-omic data platform
• Clinical data infrastructure
• Drug discovery datasets
• Precision medicine data
• Healthcare AI datasets

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Data Access Services: Omics Bank generates revenue through providing access to multi-omic, clinical, and structured EHR data from Asia and the Middle East. The company offers data packages for drug discovery, clinical development, clinical trials, and AI model development. Revenue is derived from data licensing and access fees, likely subscription or usage-based models given the enterprise sales motion.

Distribution channels3 records

Marketing channels4 records

Core offering

Omics Bank operates an AI-ready healthcare data infrastructure platform that aggregates and licenses multi-omic, clinical, and structured EHR data sourced from Asia and the Middle East (90+ hospitals, ~187 million patient lives) to support drug discovery, precision medicine, clinical trials, and healthcare AI model development. Data is extracted from EHRs using Agentic AI and LLMs, standardized to the OMOP Common Data Model and global healthcare standards (ICD-10, HL7, SNOMED, FHIR), and anonymized through patent-pending technology to be 100% regulatory-ready under HIPAA and GDPR. The platform sells access to seven data products: Longitudinal EHRs, Slides & Pathology Reports, Genomics, Transcriptomics, Proteomics, Imaging, and BioBank datasets with raw biological samples.

Product overview

OmicsBank operates as a healthcare AI-ready data infrastructure company providing a unified platform for multi-omic, clinical, and structured EHR data from Asia and the Middle East. The core offering includes seven interconnected data products: Longitudinal Electronic Health Records (OMOP CDM-structured), Slides & Pathology Reports, Genomics Data, Transcriptomics Data, Proteomics Data, Imaging Data, and BioBank Data. These products work together to support the full drug discovery and clinical development lifecycle, from early research through clinical trials and AI model development, with data standardized against global regulatory standards (HIPAA, GDPR, ICD-10, HL7, SNOMED, FHIR).

Differentiator

Problem solved

Functional benefit

Products and services

• Longitudinal Electronic Health Records (EHRs)

Quantifiable outcome

• 20X larger commercial access to anonymized data and biospecimens compared to US/EU public data
• +7 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• OwkincoreStrategic or Co-development Partner · 18 February 2026Strategic partnership with Owkin, an agentic AI company specializing in biology, to develop more inclusive biological AI and advance AI-enabled drug discovery using India's healthcare data infrastructure. The collaboration aims to address the underrepresentation of Asian and Middle Eastern populations in pharmaceutical research by developing more globally representative datasets. Owkin is seeking to expand collaborations with Indian hospitals, data providers, and pharmaceutical companies using its K Pro AI agent.
• 4baseCarecoreStrategic or Co-development Partner · 18 February 2026Strategic partnership with 4baseCare, an Indian genomics company, to develop more inclusive biological AI and advance drug discovery. The collaboration aims to leverage diverse, large-scale datasets to enhance therapeutic research and treatment options globally, with a focus on underrepresented populations in clinical research.
• BC PlatformscoreStrategic or Co-development Partner · 5 February 2026Strategic partnership with BC Platforms to expand access to large-scale real-world and multi-omics datasets from India and the UAE. The collaboration increases BC Platforms' global patient catchment to over 187 million patient lives across 35+ countries, adding approximately 12 million patients from India and 500,000 from the UAE. The partnership aims to address the under-representation of South Asian populations in global genome-wide association studies and enables advanced analytics and AI modeling for diverse patient populations in drug development and precision medicine.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BC Platforms: BC Platforms is both a strategic partner and a direct competitor — it operates a global genomic and clinical data platform (BC Unify) integrating real-world data from 35+ countries. Highly comparable to Omics Bank as both sell curated, regulatory-ready multi-omic and EHR datasets to pharma and AI customers.
• Owkin: Owkin is an agentic AI company for biology and drug discovery that partners with Omics Bank to develop biological AI using Indian and Middle Eastern data. It is directly comparable as it consumes and aggregates diverse hospital data to train AI models for pharma, with overlapping customer base.
• 4baseCare: 4baseCare is an Indian genomics company that partners with Omics Bank to expand access to Asian genomic data. Directly comparable as a genomics data provider focused on underrepresented Asian populations, with similar customers in pharma and precision medicine.
• TriNetX: TriNetX operates a global federated health research network providing clinical and genomic data for trial feasibility, protocol design, and real-world evidence. Comparable to Omics Bank in selling standardized, regulatory-grade clinical data to pharma and CROs, with similar trial recruitment use cases.

Broad incumbents

• Tempus AI: Tempus is a large, established AI-powered precision medicine company that aggregates multi-modal clinical and molecular data at massive scale. Broadly comparable in selling clinical-genomic data and AI tools to pharma, though with a much wider portfolio and a U.S./Europe-centric footprint.
• Flatiron Health: Flatiron Health, an F. Hoffmann-La Roche company, provides real-world clinical and genomic data for oncology research. Comparable in delivering EHR-derived, regulatory-grade datasets to life sciences, though focused on U.S. oncology rather than Asian/Middle Eastern multi-omic data.
• IQVIA: IQVIA is a global leader in healthcare data, analytics, and clinical research services. Directly comparable in selling clinical real-world data, biospecimens, and trial recruitment tools to pharma, with significantly broader scale and geographic reach than Omics Bank.
• Foundation Medicine: Foundation Medicine, a Roche subsidiary, provides comprehensive genomic profiling and a large clinico-genomic database for oncology. Comparable as a multi-omic data provider serving pharma research, though primarily focused on U.S./EU oncology and operating as part of a much larger enterprise.
• Verily (Alphabet): Verily is an Alphabet precision health company building real-world evidence platforms and multi-omic datasets. Comparable as a large-scale clinical and genomic data infrastructure player serving pharma, with much deeper capital and technology resources.

Emerging players

• Datavant: Datavant focuses on health data privacy, de-identification, and connectivity, enabling privacy-preserving linking of clinical and omics data. Comparable to Omics Bank's anonymization and data-infrastructure positioning, with strong overlap in HIPAA/GDPR-compliant health data exchange.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omics Bank